Theranostics

How Effective Are Gene Therapies Using Oligonucleotides for Gene Silencing?

Updated

Abstract

Less than 1% of transfected oligonucleotide-based gene therapeutics release into the cytosol, limiting their effectiveness.

  • The efficacy of oligonucleotide-based gene therapeutics (OGTs) in clinical and experimental settings is often lower than anticipated.
  • Only about 2% of tested small interfering RNAs (siRNAs) achieve the desired 70% target gene knockdown.
  • Clinically approved OGTs tend to be effective primarily for genetic disorders that lack alternative treatments, with minimal therapeutic impact.
  • Most approved OGTs and those in trials are antisense oligonucleotides (ASOs), while siRNAs have shown greater potency in cell culture studies.
  • The delayed commercialization of siRNAs may be linked to off-target effects and the ongoing development of their design strategies.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Competing interests: The authors have declared that no competing interest exists.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free